Investment appeal stands out after pullback! Canadian pipeline giant Enbridge (ENB.US) upgraded by BMO Capital to "Outperform"
BMO upgraded Enbridge to "Outperform," believing its recent pullback and $41 billion project backlog offer a good investment opportunity.
BMO Capital upgraded pipeline operator Enbridge (ENB.US) to "Outperform" from "Market Perform" with a price target of C$79.50, with analysts saying the stock's recent pullback and improved growth visibility make it an attractive investment in a volatile macroeconomic environment.
BMO analyst Ben Pham said Enbridge shares have underperformed Canadian midstream and pipeline peers year-to-date, likely due to rising bond yields, a lack of visibility into the company's roughly 5% growth guidance through the end of the decade, and a recent equity financing; meanwhile, peers are seen as having higher growth rates.
The analyst said Enbridge operates more like a diversified utility, prioritizing high-quality, long-duration contracted assets over higher-beta unconventional growth; he believes the company's scale, limited commodity exposure and diversified assets are undervalued.
"Few companies have a visible, high-quality organic growth plan like Enbridge with a secured backlog of $41 billion, plus another $20 billion of new projects expected to be sanctioned in 2026-2027," Pham said; at the same time, opportunistic acquisitions such as Salt Creek Midstream and the Tallgrass crude oil transportation business carry embedded future upside.
The analyst said Enbridge's roughly $3 billion equity financing, along with an innovative $2.7 billion joint venture with KKR for its Westcoast B.C. pipeline, have strengthened the balance sheet and provided additional financial flexibility for potential new growth opportunities.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





